Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Current Fungal Infection Reports
Published in: Current Fungal Infection Reports 2/2014

01-06-2014 | Pharmacology and Pharmacodynamics of Antifungal Agents (P Gubbins, Section Editor)

Current Antifungal Agents for Treatment of Central Nervous System Infections

Authors: Katrina S. Coulter, J. Ryan Bariola

Published in: Current Fungal Infection Reports | Issue 2/2014

Login to get access

Abstract

Invasive fungal infections have been increasing in incidence worldwide, primarily due to the growing population of immunosuppressed patients. Fungal central nervous system infections carry a high rate of morbidity and mortality due to difficulty in diagnosis and treatment. This paper provides a review of antifungal agents currently available in the United States, highlighting the pros and cons of each medication in the treatment of CNS infections. Investigational treatment approaches with combination therapy and iron chelation for CNS infections are also discussed. Despite our many advances in modern medicine, we still lack highly effective therapeutic options for treatment of cerebral infections with the angioinvasive fungi Aspergillus and the zygomycetes.
Literature
1.
McNeil MM, Nash SL, Hajjeh RA, et al. Trends in mortality due to invasive mycotic diseases in the United States, 1980-1997. Clin Infect Dis. 1; 33 (5): 641-7
2.•
Lewis RE, Cahyame-Zuniga L, Leventakos K, et al. Epidemiology and sites of involvement of invasive fungal infections in patients with haematological malignancies: a 20-year autopsy study. Mycoses. 2013;56(6):638–45. Autopsy study out of MD Anderson from 1989-2008, characterizing changes in prevalence of invasive fungal infections over this 20 year period.
3.
Lehrnbecher T, Franck C, Engles K, et al. Trends in the postmortem epidemiology of invasive fungal infections at a university hospital. J Infect. 2010;6(3):259–65.CrossRef
4.
Rex JH, Stevens DA. “Systemic Antifungal Agents”: Chapter 40. Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases, 7th ed. In: Mandell GL, Bennett JE, Dolin R, editors. Philadelphia: Elsevier Health Sci 2010. Kindle Edition.
5.
Black KE, Baden LR. Fungal Infections of the CNS: treatment strategies for the immunocompromised patient. CNS Drugs. 2007;21(4):293–318.PubMedCrossRef
6.
Hamill RJ, Sobel JD, El-Sadr W, et al. Comparison of 2 doses of liposomal amphotericin B and conventional amphotericin B deoxycholate for treatment of AIDS-associated acute cryptococcal meningitis: a randomized, double-blind clinical trial of efficacy and safety. Clin Infect Dis. 2010;31(2):225–32.CrossRef
7.
Redmond A, Dancer C, Woods M. Fungal infections of the central nervous system: a review of fungal pathogens and treatment. Neurol India. 2007;55(3):251–61.PubMedCrossRef
8.
Wong-Beringer A, Jacobs RA, Guglielmo BJ. Lipid formulations of amphotericin B: clinical efficacy and toxicities. Clin Infect Dis. 1998;27:603–18.PubMedCrossRef
9.
Barrett JP, Vardulaki KA, Conlon C, et al. A systemic review of the antifungal effectiveness and tolerability of amphotericin B formulations. Clin Ther. 2003;25(5):1295–320.PubMedCrossRef
10.
Gubbins PO, Heldenbrand S. Clinically relevant drug interactions of current antifungal agents. Mycoses. 2010;53(2):95–113.PubMedCrossRef
11.
Eriksson U, Seifert B, Schaffner A, et al. Comparison of effects of amphotericin B deoxycholate infused over 4 or 24hours: randomised controlled trial. BMJ. 2001;322(7286):579–82.PubMedCentralPubMedCrossRef
12.
Girmenia C, Cimino G, Di Cristofano F, et al. Effects of hydration with salt repletion on renal toxicity of conventional amphotericin B empirical therapy: a prospective study in patients with hematological malignancies. Support Care Cancer. 2005;13(12):987–92.PubMedCrossRef
13.
Pappas PG, Kauffman CA, Andes D, et al. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis. 2009;48:503–35.PubMedCrossRef
14.
Reed C, Bryant R, Ibrahim AS, et al. Combination polyene-caspofungin treatment of rhino-orbital-cerebral mucormycosis. Clin Infect Dis. 2008;47:364–71.PubMedCentralPubMedCrossRef
15.
White MH, Bowden RA, Sandler ES, et al. Randomized, double-blind clinical trial of amphotericin B colloidal dispersion vs. amphotericin B in the empirical treatment of fever and neutropenia. Clin Infect Dis. 1998;27:296–302.PubMedCrossRef
16.
Clemons KV, Schwartz JA, Stevens DA. Experimental central nervous system aspergillosis therapy: efficacy, drug levels and localization, immunohistopathology, and toxicity. Antimicrob Agents Chemother. 2012;56(8):4439–49.PubMedCentralPubMedCrossRef
17.
Groll AH, Giri N, Petraitis V, et al. Comparative efficacy and distribution of lipid formulations of amphotericin B in experimental Candida albicans infection of the central nervous system. J Infect Dis. 2000;182(1):274–82.PubMedCrossRef
18.
Johnson PC, Wheat LJ, Cloud GA, et al. Safety and efficacy of liposomal amphotericin B compared with conventional amphotericin B for induction therapy of histoplasmosis in patients with AIDS. Ann Intern Med. 2002;137(2):105–9.PubMedCrossRef
19.
Bellocchio S, Gaziano R, Bozza S, et al. Liposomal amphotericin B activates antifungal resistance with reduced toxicity by diverting Toll-like receptor signaling from TLR-2 to TLR-4. J Antimicrob Chemother. 2005;55:214–22.PubMedCrossRef
20.
Ben-Ami R, Lewis RE, Kontoyiannis DP. Immunopharmacology of modern antifungals. Clin Infect Dis. 2008;47:226–35.PubMedCrossRef
21.
Lewis RE, Chamilos G, Prince RA, Kontoyiannis DP. Pretreatment with empty liposomes attenuates the immunopathology of invasive pulmonary aspergillosis in corticosteroid-immunosuppressed mice. Antimicrob Agents Chemother. 2007;51(3):1078–81.PubMedCentralPubMedCrossRef
22.
Galgiani JN, Ampel NM, Blair JE, et al. Coccidioidomycosis. IDSA treatment guidelines for coccidioidomycosis. Clin Infect Dis. 2005;41:1217–23.PubMedCrossRef
23.
Mathisen G, Shelub A, Truong J, et al. Coccidioidal meningitis, clinical presentation and management in the fluconazole era. Medicine. 2010;89(5):251–84.PubMedCrossRef
24.
Walsh TJ, Anaissie EJ, Denning DW, et al. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis. 2008;46:327–60.PubMedCrossRef
25.
Pitisuttithum P, Negroni R, Graybill JR, et al. Activity of posaconazole in the treatment of central nervous system fungal infections. J Antimicrob Chemother. 2005;56:745–55.PubMedCrossRef
26.
Arndt CA, Walsh TJ, McCully CL, et al. Fluconazole penetration into cerebrospinal fluid: implications for treating fungal infections of the central nervous system. J Infect Dis. 1988;157:178–80.PubMedCrossRef
27.
Wheat LJ, Freifeld AG, Kleiman MB, et al. Clinical practice guidelines for the management of patients with histoplasmosis: 2007 update by the Infectious Diseases Society of America. Clin Infect Dis. 2007;45:807–25.PubMedCrossRef
28.
Chapman SW, Dismukes WE, Proia LA, et al. Clinical practice guidelines for the management of blastomycosis: 2008 update by the Infectious Diseases Society of America. Clin Infect Dis. 2008;46:1801–12.PubMedCrossRef
29.
Perfect JR, Dismukes WE, Dromer F, et al. Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis. 2010;50:291–322.PubMedCrossRef
30.
Haynes RR, Connolly PA, Durkin MM, et al. Antifungal therapy for central nervous system histoplasmosis, using a newly developed intracranial model of infection. J Infect Dis. 2002;185:1830–2.PubMedCrossRef
31.
Veeravagu A, Ludwig C, Camara-Quintana JQ, et al. Fungal infection of a ventriculoperitoneal shunt: histoplasmosis diagnosis and treatment. World Neurosurg. 2013;80:222e5–e13.
32.
Lutsar I, Roffey S, Troke P. Voriconazole concentrations in the cerebrospinal fluid and brain tissue of guinea pigs and immunocompromised patients. Clin Infect Dis. 2003;37:728–32.PubMedCrossRef
33.
Hebrecht R, Denning DW, Patterson TF, et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med. 2002;347(6):408–15.CrossRef
34.
Schwartz S, Ruhnke M, Ribaud P, et al. Poor efficacy of amphotericin B-based therapy in CNS aspergillosis. Mycoses. 2007;50:196–200.PubMedCrossRef
35.
36.
Kauffman CA, Bustamante B, Chapman SW, Pappas PG. Clinical practice guidelines for the management of sporotrichosis: 2007 update by the Infectious Diseases Society of America. Clin Infect Dis. 2007;45:1255–65.PubMedCrossRef
37.
38.
Letscher-Bru V, Herbrecht R. Caspofungin: the first representative of a new antifungal class. J Antimicrob Chemother. 2003;51:513–21.PubMedCrossRef
39.••
Lewis RE, Lortholary O, Roilides E, et al. How does antifungal pharmacology differ for mucormycosis versus aspergillosis. Clin Infect Dis. 2012;54(S1):S67–72. Review article highlighting the microbiological differences between Aspergillus and the mucormycoses and their effect on antifungal therapy. Includes sections on ergosterol synthesis, the fungal cell wall, MICs of antifungals, pharmacokinetic challenges, and new drug targets for mucormycosis.
40.
Feldmesser M, Kress Y, Mednick A, Casadevall A. The effect of the echinocandin analogue caspofungin on cell wall glucan synthesis by Cryptococcus neoformans. J Infect Dis. 2000;182:1791–5.PubMedCrossRef
41.
Kanetsuna F, Carbonell LM. Cell wall composition of the yeastlike and mycelial forms of Blastomyces dermatitidis. J Bacteriol. 1971;106(3):946–8.PubMedCentralPubMed
42.
43.
Flattery AM, Hickey E, Gill CJ, et al. Efficacy of caspofungin in a juvenile mouse model of central nervous system candidiasis. Antimicrob Agents Chemother. 2011;55(7):3491–7.PubMedCentralPubMedCrossRef
44.
Hope WW, Mickiene D, Petraitis V, et al. The Pharmacokinetics and Pharmacodynamics of Micafungin in Experimental Hematogenous Candida Meningoencephalitis: Implications for Echinocandin Therapy in Neonates. J Infect Dis. 2008;197:163–71.PubMedCentralPubMedCrossRef
45.
46.
Heyn K, Tredup A, Salvenmoser S, Frank-Michael CM. Effect of Voriconazole Combined with Micafungin against Candida, Aspergillus, and Scedosporium spp. and Fusarium solani. Antimicrob Agents Chemother. 2005;49(12):5157–9.PubMedCentralPubMedCrossRef
47.
Ibrahim AS, Bowman JC, Avanessian KB, et al. Caspofungin Inhibits Rhizopus oryzae 1,3-beta-d-Glucan Synthase, Lowers Burden in Brain Measured by Quantitative PCR, and Improves Survival at a Low but Not a High Dose during Murine Disseminated Zygomycosis. Antimicrob Agents Chemother. 2005;49(2):721–7.PubMedCentralPubMedCrossRef
48.
Hohl TM, Feldmesser M, Perlin DS, Pamer EG. Caspofungin Modulates Inflammatory Responses to Aspergillus fumigatus through Stage-Specific Effects on Fungal beta-Glucan Exposure. J Infect Dis. 2008;198:176–85.PubMedCentralPubMedCrossRef
49.
Lamaris GA, Lewis RE, Chamilos G, et al. Caspofungin-Mediated beta-Glucan Unmasking and Enhancement of Human Polymorphonuclear Neutrophil Activity against Aspergillus and Non-Aspergillus Hyphae. J Infect Dis. 2008;198:186–92.PubMedCrossRef
50.
Choi JH, Brummer E, Stevens DA. Combined action of micafungin, a new echinocandin, and human phagocytes for antifungal activity against Aspergillus fumigatus. Microbes Infect. 2004;6:383–9.PubMedCrossRef
51.
Garbati MA, Alasmari FA, Al-Tannir MA, Tleyjeh IM. The role of combination antifungal therapy in the treatment of invasive aspergillosis: a systemic review. Int J Infect Dis. 2012;16:e76–81.PubMedCrossRef
52.
Ibrahim AS, Gebermariam T, Fu Y, et al. The iron chelator deferasirox protects mice from mucormycosis through iron starvation. J Clin Invest. 2007;117(9):2649–57.PubMedCentralPubMedCrossRef
53.
Soman R, Gupta N, Shetty A, and Rodrigues C. Deferasirox in mucormycosis: hopefully, not defeated. J Antimicrob Chemother 2012; Research letters: 783-4
54.
Spellberg B, Ibrahim AS, Chin-Hong PV, et al. The Deferasirox-AmBisome Therapy for Mucormycosis (DEFEAT Mucor) study: a randomized, double-blinded, placebo-controlled trial. J Antimicrob Chemother. 2012;67:715–22.PubMedCentralPubMedCrossRef
55.
Saccente M, McDonnell RW, Baddour LM, et al. Cerebral histoplasmosis in the azole era: report of four cases and review. S Med Assoc. 2003;96(4):410–16.
56.
Ta M, Flowers SA, Rogers PD. The Role of Voriconazole in the Treatment of Central Nervous System Blastomycosis. Ann Pharmacother. 2009;43:1696–700.PubMedCrossRef
57.
Pikman R, Ben-Ami R. Immune modulators as adjuncts for the prevention and treatment of invasive fungal infections. Immunotherapy. 2012;4(12):1869–82.PubMedCrossRef
Metadata
Title
Current Antifungal Agents for Treatment of Central Nervous System Infections
Authors
Katrina S. Coulter
J. Ryan Bariola
Publication date
01-06-2014
Publisher
Springer US
Published in
Current Fungal Infection Reports / Issue 2/2014
Print ISSN: 1936-3761
Electronic ISSN: 1936-377X
DOI
https://doi.org/10.1007/s12281-014-0186-x

Other articles of this Issue 2/2014

Current Fungal Infection Reports 2/2014 Go to the issue

Translational Research (R Wheeler, Section Editor)

Candida albicans Niche Specialization: Features That Distinguish Biofilm Cells from Commensal Cells

Translational Research (R Wheeler, Section Editor)

Large-Scale Chromosomal Changes and Associated Fitness Consequences in Pathogenic Fungi

Pharmacology and Pharmacodynamics of Antifungal Agents (P Gubbins, Section Editor)

Cardiotoxicity Induced by Antifungal Drugs

Pharmacology and Pharmacodynamics of Antifungal Agents (P Gubbins, Section Editor)

Update on Posaconazole Pharmacokinetics: Comparison of Old and New Formulations

Translational Research (R Wheeler, Section Editor)

Essential Metals in Cryptococcus neoformans: Acquisition and Regulation

Pharmacology and Pharmacodynamics of Antifungal Agents (P Gubbins, Section Editor)

Amphotericin B: How Much Is Enough?
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits